VRT106 With Camrelizumab and Apatinib for Advanced Liver Cancer After Immunotherapy
Tests VRT106 with two other drugs in adults whose advanced liver cancer progressed after immunotherapy.
Plain-language title generated from the registry record
Registry title: A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
Key facts
- Where
- Guangzhou, ChinaSee the site
- Phase
- Phase 2/3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07589244, who can take part
Where in China
- The Third Affiliated Hospital of Sun Yat-Sen UniversityGuangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Guangzhou Virotech Pharmaceutical Co., Ltd.
- Trial code
- NCT07589244
- Record updated
- 30 October 2026
- Original description
This is an open-label phase II/III clinical trial enrolling patients with advanced HCC who have failed prior ICIs. The phase II portion consists of a part A dose-escalation stage and a part B dose-expansion stage. The phase III study will be initiated following discussions with National Medical Products Administration (NMPA) regarding the phase III protocol, based on accumulated data from phase II including safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD).Read full original descriptionShow less
A Multicenter, Open-label Phase II/III Clinical Trial of VRT106 in Combination With Camrelizumab and Apatinib in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Immune Checkpoint Inhibitor Therapy
This is an open-label phase II/III clinical trial enrolling patients with advanced HCC who have failed prior ICIs. The phase II portion consists of a part A dose-escalation stage and a part B dose-expansion stage. The phase III study will be initiated following discussions with National Medical Products Administration (NMPA) regarding the phase III protocol, based on accumulated data from phase II including safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD).
Inclusion: Voluntarily sign the informed consent form (ICF), understand the nature of this study, and agree to comply with and complete all required study procedures; Be aged between 18 and 75 years (inclusive) on the date of signing the ICF, regardless of gender; Have a histologically or cytologically confirmed diagnosis of advanced hepatocellular carcinoma (HCC), or a clinical diagnosis of advanced HCC according to the Standard for Diagnosis and Treatment of Primary Liver Cancer(2024 Edition); Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1; Have an anticipated life expectancy of ≥ 3 months; Have no severe hematologic, hepatic, renal, coagulation, or cardiac function abnormalities.
Exclusion: Prior receipt of camrelizumab, apatinib, oncolytic viruses, or other gene therapies; Receipt of other unapproved investigational drugs/devices within 4 weeks or 5 half-lives (whichever is shorter) prior to first dose administration in this study, or immunocompromised status; History of splenectomy; Pregnant or breastfeeding women.